FDA Approved: FOCALIN XR — Supplemental Application (Sandoz Inc)

View source ↗

Summary

The FDA approved a supplemental application for FOCALIN XR submitted by Sandoz Inc., involving dexmethylphenidate hydrochloride.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• FOCALIN XR (DEXMETHYLPHENIDATE HYDROCHLORIDE)

Snippet

SUPPL AP for FOCALIN XR (DEXMETHYLPHENIDATE HYDROCHLORIDE)